PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma.
Saved in:
| Title: | PKMYT1 is a Targetable Vulnerability in del(17p) High-Risk Multiple Myeloma. |
|---|---|
| Authors: | Schavgoulidze A; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Cui J; 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA, United States., Encinas J; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts., United States., Favasuli VK; Candiolo Cancer Institute, FPO-IRCCS, Candiolo (TO), Italy., Talluri S; DFCI, Boston, Massachusetts, United States., Mahéo S; IUCT, TOULOUSE, France., Cerutti C; Institut Universitaire du Cancer de Toulouse-Oncopole, 31100, France., Shammas MA; Dana Farber Cancer Institute, Boston, Massachusetts, United States., Primo D; Vivia Biotech, Madrid, Spain., Vicente C; University of Navarra, Pamplona, Spain., Larrayoz M; CIMA, Pamplona, Spain., Martínez-Climent JA; Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain., Anderson KC; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Aktas Samur A; Dana Farber Cancer Institution, Boston, Massachusetts, United States., Samur MK; Dana-Farber Cancer Institute and Harvard School of Public Health, Boston, Massachusetts, United States., Avet-Loiseau H; University Hospital, Sarzeau, France., Corre J; Unité de Genomique du Myélome, IUC- T Oncopole, TOULOUSE, France., Munshi NC; Dana Farber Cancer Institute, Boston, Massachusetts, United States., Fulciniti M; Dana Farber Cancer Institute, Boston, Massachusetts, United States. |
| Source: | Blood [Blood] 2026 Jun 03. Date of Electronic Publication: 2026 Jun 03. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Country of Publication: United States NLM ID: 7603509 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1528-0020 (Electronic) Linking ISSN: 00064971 NLM ISO Abbreviation: Blood Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
